Efficacy and Safety of Ivonescimab as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma. Presented by Dr. Jun Guo, #ESMO26 written coverage by @rksayyid > https://bit.ly/4yCDLDt #KidneyCancer #RCC #Immunotherapy @myESMO